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therapy for heart failure patients who cannot receive transvenous
epicardial cardiac resynchronization therapy (CRT) or have not re-
sponded adequately to CRT. BiV ENDO CRT can be delivered by a
new wireless LV ENDO pacing system (WiSE-CRT system; EBR Sys-
tems, Sunnyvale, CA), without the requirement for lifelong antico-
agulation.
OBJECTIVE The purpose of this study was to assess the safety and
efficacy of the WiSE-CRT system during real-world clinical use in an
international registry.
METHODS Data were prospectively collected from 14 centers
implanting the WiSE-CRT system as part of the WiCS-LV Post Market
Surveillance Registry. (ClinicalTrials.gov Identifier: NCT02610673).Dr Sieniewicz is supported by a British Heart Foundation Project Grant. Dr Betts
research funding and/or consultancy fees from Abbott, Medtronic Inc, Boston, and L
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licenses/by-nc-nd/4.0/).RESULTS Ninety patients from 14 European centers underwent im-
plantation with the WiSE-CRT system. Patients were predominantly
male, age 68.2 6 10.5 years, left ventricular ejection fraction
30.6% 6 8.9%, mean QRS duration 180.7 6 27.0 ms, and 40%
with ischemic etiology. Successful implantation and delivery of
BiV ENDO pacing was achieved in 94.4% of patients. Acute (,24
hours), 1- to 30-day, and 1- to 6-month complications rates were
4.4%, 18.8%, and 6.7%, respectively. Five deaths (5.6%) occurred
within 6 months (3 procedure related). Seventy percent of patients
had improvement in heart failure symptoms.
CONCLUSION BiV ENDO pacing with the WiSE-CRT system seems to
be technically feasible, with a high success rate. Three procedural
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1292 Heart Rhythm, Vol 17, No 8, August 2020adequate operator training and implantation at centers with immedi-
ately available cardiothoracic and vascular surgical support.
KEYWORDS Cardiac resynchronization therapy; Endocardial pacing;
Heart failure; Leadless pacing; NonresponderFigure 1 The WiSE-CRT pacing system.(Heart Rhythm 2020;17:1291–1297) © 2020 The Authors. Pub-
lished by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Heart failure is a significant cause of morbidity and mortal-
ity,1 with disease progression resulting in adverse left ven-
tricular (LV) remodeling and dyssynchronous electrical and
mechanical activation.2 Cardiac resynchronization therapy
(CRT) restores regional activation synchrony and enhances
cardiac contractility.3 However, 30%–50% of patients do
not show improvement with conventional CRT delivered
from an epicardial LV lead within a tributary of the coronary
sinus.4–6 In addition, implantation of an epicardial LV lead is
not always possible due to technical and anatomic
limitations,7 particularly in patients undergoing an upgrade
from a pre-existing cardiac implantable electronic device
because of central venous stenosis/occlusion.8
LV endocardial pacing is a potential therapy for patients
who either cannot receive transvenous epicardial CRT or
have not responded adequately to CRT.9 LV endocardial
stimulation traditionally has been delivered via pacing leads
placed transseptally, which mandates lifelong anticoagula-
tion due to the risk of thromboembolic complications. A
novel wireless LV endocardial pacing system (WiSE-CRT
system; EBR Systems, Sunnyvale, CA) delivers electrical
stimulation to the LV endocardial surface of the heart by
transducing acoustic energy from an ultrasound (US) pulse
generator implanted subcutaneously in an intercostal space
(Figures 1 and 2).10 The US waves are converted to electrical
stimulation energy by a small receiver electrode deployed
percutaneously into the LV cavity. The receiver electrode
is fully endothelialized after four weeks, avoiding the needfor long-term anticoagulation. The stimulation is triggered
by right ventricular (RV) pacing, resulting in near simulta-
neous (w2–5 ms) LV and RV endocardial activation. Pa-
tients must be prescreened using a combination of linear
and cardiac US (echocardiography) to ensure successful
delivery of consistent LV endocardial pacing from the most
efficient location.
The system has undergone a first-in-man study evalua-
tion.11 More recently, in the nonrandomized SELECT-LV
(Safety and Performance of Electrodes implanted in the
Left Ventricle) study, 35 patients across 6 centers were im-
planted, and promising results were seen in terms of clinical
response and LV reverse remodeling.12 Previous work also
evaluated the possibility of identifying and targeting the
optimal pacing site.13 The WICS-LV Post Market Surveil-
lance Registry (ClinicalTrials.gov Identifier:
NCT02610673) was undertaken to assess the safety and effi-
cacy of the WISE-CRT system in a real-world setting. The
device is CE (Conformité Européenne [French for European
Conformity]) marked in Europe and is indicated for patients
who are unable to receive conventional CRT or who are non-
responders to CRT.Methods
Data collection
The WICS-LV Post Market Surveillance Registry prospec-
tively collected data from all 14 European centers implanting
the WiSE-CRT System. All patients studied provided full
written consent to participate. Patient data was de-identified
and collected anonymously using a uniquely identifiable
study number.
Inclusion criteria
The WiSE-CRT system is CE marked for 3 approved indica-
tions12: (1) patients in whom LV lead deployment was not
possible or had previously failed due to anatomic constraints,
high capture thresholds, or phrenic nerve stimulation; (2) pa-
tients undergoing an upgrade to CRT in whom implantation
of an LV lead was impractical or complex due to issues with
venous access or undesirable because of previous pocket
infection; and (3) patients who previously were nonre-
sponders to conventional transvenous epicardial CRT. Non-
responders were defined as patients who had no change or
had worsening of symptoms or New York Heart Association
functional class after 6 months of treatment as confirmed by
the treating physician. Patients were classified as having
either ischemic cardiomyopathy or nonischemic cardiomy-
opathy using a combination of cardiac magnetic resonance
imaging, electroanatomic mapping, coronary angiography,
and clinical history.
Figure 2 A: The WiSE-CRT delivery catheter across the aortic valve, with the pacing electrode advanced to the tip of the catheter and about to be deployed in
themyocardium. The battery and ultrasound (US) pulse generator also are visible.B:TheWiSE-CRT electrode affixed to the myocardium after release.C: Poster-
oanterior view of the Micra transcatheter pacing system (TPS) (Medtronic Inc, Minneapolis, MN) and theWiSE-CRT US pulse generator and pacing electrode in
situ.D:Right anterior oblique view of theMicra TPS andWiSE-CRTUS pulse generator, battery, and pacing electrode.E: Posterior chest radiograph showing the
WiSE-CRT system in situ in combination with the Micra TPS. F: Lateral chest radiograph showing the WiSE-CRT system in situ in combination with the Micra
TPS.
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Three safety and efficacy assessments were prespecified: (1)
Procedural success, requiring successful implantation of all
WiSE-CRT components and confirmation of biventricular
pacing on a postimplant 12-lead electrocardiogram. (2)
Safety of the system, evaluating acute (,24 hours), interme-
diate (24 hours–1 month), and long-term (1–6 months) com-
plications. Adjudication was performed by the local principal
investigator at each site. (3) Clinical response to biventricular
endocardial pacing, assessing the proportion of patients who
experienced improvement in clinical symptoms 6 months af-
ter implantation.Clinical response
Clinical response was assessed by a clinical composite score.
This simple global assessment of symptoms classified each
patient into 1 of 3 categories: improved, worsened, or un-
changed.Statistical analysis
Continuous variables with a gaussian distribution are given
as mean6 SD. Significance testing on continuous, normallydistributed paired data was performed using 2-tailed paired
Student t tests. Significance testing on continuous, non-
normally distributed paired data was performed using the
Wilcoxon signed rank test. Significance testing on contin-
uous, non-normally distributed unpaired data was performed
using the Mann-Whitney U test. If both independent and
dependent factors were categorical, significance testing was
performed using the c2 test. Odds ratios were calculated us-
ing binary logistic regression. If both independent and depen-
dent factors were continuous, odds ratios and significance
testing were performed using linear regression. P ,.05 was
considered significant. Analysis was performed using
PASW Statistics 24 (SPSS Inc, Chicago, IL).Results
Patient characteristics
A total of 90 patients from 14 European centers were im-
planted with the WiSE-CRT system (Table 1). Patients
were predominantly male (80.0%) (mean age 68.2 6 10.5
years; mean left ventricular ejection fraction 30.6% 6
8.9%). Mean QRS duration was 180.7 6 27.0 ms, and
40.0% of patients had an ischemic etiology. In terms of
Table 1 Patient characteristics
No. of patients 90
Age (y) 68.2 6 10.5
Male 72 (80.0)







LVEF (%) 30.6 6 8.9
LVESV (ml) 130.4 6 78.5
LVEDV (ml) 185.7 6 93.0
ECG
Atrial arrhythmia 47 (52.2)
QRS duration (ms) 180.7 6 27.0
RV paced morphology 81 (90.0)
LBBB morphology 6 (6.7)
BiV paced morphology 3 (3.3)
Indication
Failed LV lead implant 44 (48.9)
Complex upgrade 34 (37.8)
Failure to respond to CRT 12 (13.3)
Values are given as n (%) or mean 6 SD unless otherwise indicated.
BiV5 biventricular; ECG5 electrocardiography; ICM5 ischemic cardio-
myopathy; LBBB 5 left bundle branch block; LV 5 left ventricle; LVEDV 5
left ventricular end-diastolic volume; LVEF 5 left ventricular ejection frac-
tion; LVESV5 left ventricular end-systolic volume; NYHA5 New York Heart
Association; RV 5 right ventricle.
Table 2 Patient safety outcome data
Complication data No. (%)
1294 Heart Rhythm, Vol 17, No 8, August 2020indication, 48.9% of patients had failed conventional transve-
nous CRT implant, 37.8% were deemed a complex upgrade,
and 13.3% previously were nonresponders to epicardial
CRT. Four patients (4.4%) withdrew from the registry after
undergoing implantation with the system, so no follow-up
data for these patients were recorded. The majority of patients
(n5 82) were implanted via the femoral artery using a retro-
grade transaortic approach as previously described.10 In a mi-
nority of patients in whom issues with arterial patency,
tortuosity, or aortic valve disease/replacement precluded a
retrograde approach (n 510), a novel transseptal approach
was used.14Patient deaths within the registry 5 (5.6)
Procedure related 3
Nonprocedure related 2Procedural successAcute (,24 h) 4 (4.4)
Cardiac tamponade 2
Pneumothorax/pleural effusion 2
Intermediate (.24 h–1 mo) 17 (18.8)
Death 1
Arterial access complication 4
Pocket hematoma (generator) 4
Postprocedure chest sepsis 3
Pocket infection (generator) 3
Acute kidney injury 2
Chronic (1–6 mo) 6 (6.7)
Death 4
CVA 1
Extrastimulation during TTE 1
CVA 5 cerebrovascular accident; TTE 5 transthoracic echocardiographyConfirmation of biventricular pacing
Biventricular pacing was confirmed by postimplantation 12-
lead electrocardiogram in 85 of 90 patients (94.4%). In 5
cases (5.6%), consistent capture of the LV endocardial pac-
ing electrode could not be achieved. Failure of the screening
process to exclude 2 unsuitable patients was later confirmed:
the first patient had comorbid chronic obstructive pulmonary
disease with significant lung encroachment affecting the US
signal between the subcutaneous transmitter array and LV
endocardial pacing electrode; and the second patient had a
distance between the LV pacing electrode to US array that
was too large (.13 cm) to allow achievement of consistentcapture. One patient never received an LV pacing electrode
due to periprocedural tamponade, which led to the implant
procedure being aborted. One patient experienced subopti-
mal device functionality after the US transmitter displaced
due to improper initial fixation, and revision with a new US
transmitter resolved the issue. In the final patient, the elec-
trode was believed to be implanted in myocardial scar, and
delivery of LV stimulation resulted in intermittent capture.Safety and complicationsAcute complications
Procedural acute complications (,24 hours) occurred in 4
patients (4.4%) (Table 2). Two patients experienced cardiac
tamponade after electrode placement, and 1 of these patients
died 4 days later (see section on Intermediate complications).
Two patients had complications related to US transmitter
array/battery placement (1 pneumothorax, 1 pleural effu-
sion). Neither patient required intervention, and both
resolved with conservative management. No electrode embo-
lizations occurred.Intermediate complications
Intermediate complications (24 hours–1 month) occurred in
17 patients (18.8%), including 1 patient death that occurred
4 days postimplant, which was attributed to an acute LV
perforation that resulted in cardiac tamponade. The most
common adverse events were related to femoral arterial ac-
cess in 4 patients (4.4%): 1 femoral hematoma that resolved
with conservative management and 3 femoral artery pseu-
doaneurysms, 2 of which required surgical intervention.
Four patients (4.4%) had transmitter/battery pocket hema-
tomas, and 3 patients (3.3%) had transmitter/generator pocket
infection. Three patients (3.3%) had postprocedural lower
respiratory tract infection, and 2 patients had postprocedural
acute kidney injury.
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Chronic complications (1–6 months) occurred in 6 patients,
including 4 deaths (2 believed to be procedure/device
related). One patient with persistent atrial fibrillation treated
with apixaban suffered a cerebellar infarct 5 months postim-
plant. Given that the receiver electrode endothelializes
within 4–6 weeks, this complication was not believed to
be procedure or device related. Stimulation of the WiSE-
CRT system during echocardiography was observed in 1
patient at the 6-month follow-up visit. The receiver elec-
trode had been positioned in an LV apical position. The
sonographer observed a self-terminating run of ectopic ven-
tricular extrasystoles while obtaining an apical 4-chamber
view. The run of ectopic beats stopped immediately after
the probe was withdrawn, and the patient reported no
symptoms.
Learning curve and success/complications
Most of the complications (76%) occurred within a center’s
first 10 cases, suggesting an initial learning curve when using
this technology.
Patient deaths
Five patients (5.6%) died within 6 months of implantation.
Three deaths (3.3%) were adjudicated to be procedure/device
related, 2 of which were related to LV perforation. Details of
patient deaths are given in the Supplemental Information—
Patient Deaths.
CRT response
Four patients who were lost to follow-up were excluded
from the chronic response analysis. All 86 patients who
received CRT at 6 months had data evaluating their clinical
response. Sixty patients (69.8%) reported an improved clin-
ical composite score; 12 (14.0%) had no change in compos-
ite score; and 4 (4.7%) had a worsened composite score. The
group of 86 patients included 5 who experienced inconsis-
tent LV endocardial stimulation and 5 who died during
follow-up. Comprehensive echocardiographic study of LV
volumes to assess remodeling was available for 43 patients
and can be reviewed in the Supplemental Information—
Echocardiographic Remodeling and Supplemental Table 1.Discussion
The WICS-LV Post Market Surveillance Registry is the
largest experience to date of this novel technology to achieve
leadless LV endocardial pacing. The registry was designed to
assess the procedural success, safety, and long-term efficacy
of leadless LV endocardial pacing in a real-world setting of
14 European centers.
The principal findings were as follows. (1) The WiSE-
CRT system achieved procedural success, with biventricular
endocardial pacing confirmed in .94% of patients. (2)
Device/procedural-related adverse events occurred in a sig-
nificant number of patients. Three procedural deaths (3.3%)
occurred; 4.4% of patients had a procedural complicationwithin 24 hours of the procedure; 18.8% had a complication
between 24 hours and 1 month after the procedure; and 6.7%
had a complication between 1 and 6 months after the proced-
ure. (3) At 6 months, the system was associated with a favor-
able clinical response rate of 70%.Comparison with previous studies
The WiSE-CRT Post Market Surveillance Registry repre-
sents the largest evaluation of this novel pacing technology
and establishes that real-world use of the WiSE-CRT LV
endocardial pacing system is effective. It has a complication
profile and response rate similar to those seen in the
SELECT-LV study,12 a prospective multicenter nonrandom-
ized trial that assessed the safety and performance of the
WiSE-CRT system in 35 patients. Similar to the current
study, SELECT-LV reported successful implantation of the
system in 97% of cases. Similar rates of clinical response
of 84.8% and 70% of patients reporting an improvement in
clinical composite score were observed in the SELECT-LV
study and the WiSE-CRT registry, respectively.
Both studies identified a significant complication rate. No
episodes of cardiac tamponade were observed in the
SELECT-LV trial; however, 2 patients (2.2%) were identi-
fied in the WiSE-CRT registry and subsequently died.
Serious acute (,24 hours) procedure/device-related events
occurred in 4 patients (8.6%) in the SELECT-LV study
compared to 4.4% in the WiSE-CRT registry. A serious
procedure/device-related event occurred between 24 hours
and 1 month after the procedure in 22.3% of patients in the
SELECT-LV trial, with a similar rate of events (18.8%) in
the WiSE-CRT registry. In the SELECT-LV trial 1
procedure-related death (2.8%) following VF at the time of
electrode placement was reported, whereas in the WiSE-
CRT registry 5 patient deaths (5.6%) occurred within a 6-
month period, 3 (3.3%) of which were believed to be proced-
ure related. The rate of perforation in the current registry has
improved compared to the initial iteration of the device,
which had an 18% tamponade rate and led to redesign of
the delivery catheter.10
A lead-based system for endocardial CRT was previously
analyzed in the ALSYNC (ALternate Site Cardiac Re-
sYNChronization) study.9 This prospective study enrolled
138 patients who either had a failed attempt at conventional
transvenous epicardial CRT or were unsuitable to undergo bi-
ventricular resynchronization pacing. The primary study
objective was to investigate the safety at 6 months of deliv-
ering LV endocardial pacing via a lead placed across the
atrial septum. The implant success rate was 89.4%, which
is consistent with our registry findings. Freedom from com-
plications meeting the definition of primary endpoint was
82.2% at 6 months. Fourteen transient ischemic attacks (9 pa-
tients [6.8%]), 5 nondisabling strokes (5 patients [3.8%]), and
23 deaths (17.4%) were reported. No death resulted from a
primary endpoint complication. At 6 months, New York
Heart Association functional class improved in 59% of pa-
tients. Therefore, the current registry has a death rate at
1296 Heart Rhythm, Vol 17, No 8, August 2020follow-up lower than that observed in the ALSYNC study
and a significantly reduced risk of cerebrovascular events.Vascular access complications
The most common procedural complications were related to
femoral arterial access, as the WiSE-CRT system was de-
signed to allow deployment of the pacing electrode in the
LV cavity via retrograde aortic access from the femoral ar-
tery. This procedure requires large-bore 12F femoral arterial
access and closure, skills not commonly required by prac-
ticing electrophysiology/complex device specialists who
tend to implant this system. Three approaches have been
devised to reduce the rate of femoral arterial access compli-
cations. First, vascular closure devices were used at 12 cen-
ters to minimize bleeding and ensure effective arterial
closure at the end of the procedure. Eleven centers used the
Perclose ProGlide, Abbott Vascular (Santa Clara, California)
vascular suture system. One center used the Prostar XL
(Abbott Vascular) percutaneous vascular surgical system to
assist vascular hemostasis. Vascular closure systems have
been shown to reduce time to hemostasis.15
Second, several operators have used pre- and periproce-
dural imaging to guide arterial access. Five centers used
real-time US guidance to identify the femoral artery and visu-
alize guidewire deployment. At one center, a contralateral
femoral puncture was performed in order to facilitate an ipsi-
lateral femoral angiogram before obtaining large-bore femoral
access. Third, use of a transseptal approach permitting elec-
trode deployment in the LV endocardium after initial femoral
venous access has been shown to be possible.14 In a series of
10 cases, this approach obviated the requirement for femoral
arterial access, achieving successful electrode deployment
without a single groin or thromboembolic complication.16
This approach may be preferable among electrophysiologists
who are familiar with performing transseptal punctures.US extrastimulation
The WiSE-CRT receiver electrode typically is not sensitive
to routine US imaging, but in rare instances extrastimulation
of the device is possible. In our series, this event was
observed in only 1 case. However, this is an important finding
given the widespread use of ultrasonic imaging in medicine
and specifically within the field of cardiology. Apical place-
ment of the LV pacing electrode seems to increase the poten-
tial for extrastimulation, particularly while obtaining an
apical 4-chamber view with transthoracic echocardiography,
which significantly reduces the distance between the receiver
electrode and the alternate US source. Other risk factors for
extrastimulation include the use of high-power settings,
low-frequency US (typically utilized during harmonic imag-
ing), and thin body habitus. In order to avoid inadvertent
extrastimulation of the pacing electrode, all patients are
issued a medical device identification card stating they
have a US-sensitive pacemaker. For cases in which apical
deployment of the pacing electrode has been confirmed, an
alternative echocardiography protocol has been developedand shown to successfully prevent further extrastimulation.
This document forms part of the clinical trial documents
for the SOLVE CRT Clinical Trial (ClinicalTrials.gov Iden-
tifier: NCT02922036). Echocardiography Acquisition and
Transfer Manual: The SOLVE-CRT Trial (Version 5.0, 19
Dec 2019).Study limitations
The main limitation of this current analysis is that it is a reg-
istry and therefore is limited by the inherent constraints of a
nonrandomized study. Importantly, neither patients nor in-
vestigators were blinded, and all suitable patients enrolled
in the WiCS-LV registry were implanted with the system.
Although LV reverse remodeling was selected as an
endpoint, other endpoints included the subjective clinical
response, which may be more open to bias. A randomized,
double-blinded evaluation of the WiSE-CRT system is
currently underway (Stimulation Of the Left Ventricular
Endocardium for Cardiac Resynchronization Therapy in
Non-Responders and Previously Untreatable Patients
(SOLVE CRT; ClinicalTrials.gov Identifier:
NCT02922036). This study hopefully will provide an unbi-
ased assessment of symptomatic and echocardiographic
response associated with endocardial pacing.
Unlike conventional transvenous epicardial CRT, the
WiSE-CRT system is unable to determine the percentage of
effective CRT pacing. When interrogating the WiSE-CRT
system using the pacing system analyzer, the number of
“tracked” RV pacing signals that result in generation of a
US wave can be evaluated but not whether the US signal re-
sulted in successful LV endocardial capture. LV capture can
only be confirmed by assessing the paced QRS morphology
for successful biventricular paced morphology. Holter moni-
toring can be used to confirm consistent biventricular capture
when required.
Finally, comprehensive LV volume data for all patients
were not available for data analysis. Comprehensive echocar-
diographic study of LV volumes to assess remodeling was
available for 43 patients. Fourteen patients were excluded
from chronic response analysis due to failure to achieve
endocardial stimulation in 5, death during follow-up in 5,
and loss to follow-up in 4. LV volumetric assessment either
was not performed or was of insufficient quality to allow
for meaningful data analysis in 33 patients.Conclusion
The WICS-LV Post Market Surveillance Registry is the
largest series of leadless LV endocardial pacing to date.
Importantly it demonstrates effective real-world use with a
response rate similar to those of previous nonrandomized
studies, with nearly 70% of patients reporting an improve-
ment in clinical symptoms. Response rates are equivalent
to those of lead-based biventricular endocardial pacing sys-
tems while largely eliminating the risk of thromboembolic
stroke.9 Implantation of the system can be associated with
a significant complication rate, but complications will occur
Sieniewicz et al Real-World Leadless CRT 1297less frequently as operators gain more experience with the de-
livery system. The risk of cardiac tamponade is in keeping
with other left-sided vascular procedures such as left atrial
appendage occlusion,17 and given the risk of cardiac tampo-
nade, which may require urgent repair, implantation should
be performed at centers with on-site cardiothoracic surgical
facilities. Our results suggest that endocardial CRT pacing
with this novel pacing system is effective treatment for a
group of high-risk patients with heart failure who either
cannot receive or who have not responded to conventional
CRT. Implantation of the system should be performed by
adequately trained operators at centers having experience
with vascular and cardiothoracic complications.
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